secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2026-10-21T12:07:22+00:00
Accession:  0001193125-26-427224
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Voyager Therapeutics names Robin Swartz President; slated to succeed CEO Sandrock after Q1 2027 VY1706 safety data
--------------------------------------------------------------------------------

- Swartz, 56, becomes President effective Oct 20, 2026; she has been COO and Chief Business Officer since Nov 2024 and Principal Financial Officer/Treasurer since May 2026.
- CEO transition expected after initial acute safety data from the VY1706 trial in early Alzheimer's, anticipated in Q1 2027; Alfred Sandrock is expected to remain on the Board.
- Swartz base salary $625,000 with a 50% target bonus; she receives an option for 318,500 shares and 68,250 RSUs granted Nov 1, 2026 under the 2025 Stock Incentive Plan.
- Severance on termination without cause or for good reason: 12 months base salary, pro rata target bonus and up to 12 months COBRA; full equity acceleration if within 12 months after a sale event.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000119312526427224/0001193125-26-427224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000119312526427224/d157795d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-427224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer